Oseltamivir News and Research

RSS

TGen to secure emergency FDA approval for 2009 H1N1 flu test

The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.

30 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

FDA urges consumers to exercise care on online H1N1 drug products

The U.S. Food and Drug Administration today warned consumers to use extreme care when purchasing any products over the Internet that claim to diagnose, prevent, treat or cure the H1N1 influenza virus.

19 Oct 2009

H1N1 illness in young Mexican patients associated with severe acute respiratory distress syndrome

Critical illness from 2009 influenza A(H1N1) in Mexico occurred among young patients, was associated with severe acute respiratory distress syndrome and shock, and had a fatality rate of about 40 percent, according to a study to appear in the November 4 issue of JAMA.

12 Oct 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

FluCide more effective than Tamiflu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.

15 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009

New Influenza A/H1N1 detection kit launched

QIAGEN, today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance of the swine flu pandemic. QIAGEN’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes “swine flu”, as well as of all other known Influenza A and B virus strains.

10 Sep 2009

Members of Blue Shield of California to receive administrative costs of the H1N1 virus vaccine

Blue Shield of California announced today that it will cover the administrative costs of the H1N1 virus (swine flu) vaccine for all its members, regardless of which plan they have. Blue Shield will be waiving prior authorizations, copays and deductibles for office visits when members go to an in-network doctor to get H1N1 vaccinations.

9 Sep 2009

Phase III trials for CS-8958 neuraminidase inhibitor successful

Hovione is pleased to announce that its TwinCaps(R) inhaler licensees Daiichi Sankyo Co. Ltd. (Tokyo, Japan) and Biota Holdings Ltd (Victoria, Australia) have both announced successful Phase III trials for CS-8958, a new long-acting neuraminidase inhibitor for treatment of influenza (known as a prodrug of laninamivir).

9 Sep 2009

ViraCor-IBT Laboratories launches new influenza and respiratory virus testing service

ViraCor-IBT Laboratories today launched a new, comprehensive influenza and respiratory virus testing service that will assist physicians in detecting a range of respiratory viruses including 2009 Influenza A H1N1, or “swine flu,” as well as other influenza subtypes and common respiratory viruses such as rhinovirus, respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).

31 Aug 2009

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

22 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009

Tamiflu-resistant swine flu identified along Texas-Mexico border

PAHO on Monday announced it had found Tamiflu-resistant H1N1 (swine) flu along the Texas-Mexico border, Agence-France Press reports. The discovery of several cases in El Paso and McAllen, Texas, adds the U.S. to a growing list of countries with antiviral-resistant H1N1, such as Canada, Denmark, Hong Kong and Japan. "Experts had gathered in La Jolla on Monday to discuss the response to the outbreak, and warned that resistant strains were likely emerging because of overuse of antivirals like Tamiflu," the news service writes (8/3).

4 Aug 2009

Sanofi-Aventis, GlaxoSmithKline will donate influenza vaccines to WHO

The drugmaker Sanofi-Aventis will donate millions of doses of a vaccine that offers protection against the H1N1 (swine flu) virus to the WHO once the vaccine is ready, the company's chief executive officer announced Tuesday, Reuters reports (Elsner, Reuters, 6/17).

18 Jun 2009

Targeting children may be an effective use of limited supplies of flu vaccine

Targeting children may be an effective use of limited supplies of flu vaccine, according to research funded by the Wellcome Trust and the EU. The study suggests that, used to support other control measures, this could help control the spread of pandemics such as the current swine flu.

17 Jun 2009

Research finds Tamiflu and Relenza relatively safe for use in pregnancy

With the H1N1 flu outbreak now elevated to pandemic level, a new article in CMAJ (Canadian Medical Association Journal) reports that oseltamivir (Tamiflu) and zanamivir (Relenza) are relatively safe drugs for use in pregnant and breast-feeding women.

15 Jun 2009

Recommendations by experts to WHO on influenza A (H1N1) vaccines

Current epidemiological information suggests that the influenza A (H1N1) virus transmissibility potential is at least comparable to that of seasonal influenza viruses, with ability to sustain community spread. There is therefore no reason to expect that ongoing spread of the virus will stop.

19 May 2009